Zoetis Inc. $ZTS Shares Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 80.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 76,113 shares of the company’s stock after acquiring an additional 33,873 shares during the period. Wealthfront Advisers LLC’s holdings in Zoetis were worth $5,469,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of ZTS. RFG Advisory LLC boosted its position in Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares in the last quarter. Quest 10 Wealth Builders Inc. lifted its stake in shares of Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after purchasing an additional 86 shares during the period. Financial Engines Advisors L.L.C. lifted its stake in shares of Zoetis by 4.4% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after purchasing an additional 87 shares during the period. Physician Wealth Advisors Inc. boosted its holdings in Zoetis by 17.4% during the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after buying an additional 91 shares in the last quarter. Finally, Smithfield Trust Co grew its position in Zoetis by 4.2% during the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after buying an additional 92 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. BNP Paribas Exane cut their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Weiss Ratings lowered Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, TD Cowen dropped their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $109.23.

Zoetis Trading Down 2.0%

Shares of ZTS opened at $75.13 on Friday. Zoetis Inc. has a 52-week low of $71.00 and a 52-week high of $159.00. The stock has a market cap of $31.05 billion, a PE ratio of 12.38, a price-to-earnings-growth ratio of 1.79 and a beta of 0.74. The firm’s fifty day moving average is $75.79 and its two-hundred day moving average is $97.47. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.